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Abstract
Background: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA), and is designated
RA-associated ILD (RA-ILD). RA-ILD has a large impact on the prognosis of RA. Here, we investigated the micro RNAs
(miRNAs) profiles to determine whether they may be useful for diagnosing RA-ILD.
Methods: RNA was isolated from plasma samples and cDNA was synthesized. Real-time RT-PCR analysis was
performed to evaluate 752 miRNA expression profiles in plasma pools from RA patients with or without RA-ILD.
Sixteen selected miRNA levels were analyzed in individual plasmas from 64 RA patients with or without RA-ILD.
Results: Expression levels of hsa-miR-214-5p (mean relative expression level ± standard deviation, 8.1 ± 28.2 in RA
with ILD, 0.2 ± 0.9 in RA without ILD, P = 0.0156) and hsa-miR-7-5p (56.2 ± 260.4 in RA with ILD, 4.7 ± 11.8 in RA
without ILD, P = 0.0362) were higher in RA patients with RA-ILD than in those without. The values of miRNA index
(214, 7) generated from hsa-miR-214-5p and hsa-miR-7-5p for ILD were significantly elevated in RA patients with
RA-ILD compared with those without (0.122 ± 0.332 in RA with ILD, 0.006 ± 0.013 in RA without ILD, P = 0.0010). The
area under the curve value of the receiver operating characteristic curve for the miRNA index (214, 7) was 0.740.
Conclusions: To the best of our knowledge, this is the first report of miRNA profiles in RA-ILD. The expression
levels of hsa-miR-214-5p and hsa-miR-7-5p were increased in RA with ILD.
Keywords: miRNA profile, Rheumatoid arthritis, Interstitial lung disease, Biological marker
Background
Rheumatoid arthritis (RA) is a chronic systemic inflam-
matory autoimmune disease with bone and joint de-
struction. It is well known that interstitial lung disease
(ILD) is frequently associated with RA [1]. Although
nonspecific interstitial pneumonia (NSIP) pattern is pre-
dominantly observed in collagen disease patients with
ILD, usual interstitial pneumonia (UIP) pattern is often
observed in RA-associated ILD (RA-ILD) patients [2].
The prognosis of idiopathic interstitial pneumonia pa-
tients with UIP pattern was reported to be worse than
those with NSIP [3]. The presence of ILD influences the
prognosis of RA [4, 5]. Krebs von den lungen-6 (KL-6)
and surfactant protein-D (SP-D) have been used as bio-
markers for ILD, but have low sensitivity for the detec-
tion of RA-ILD [6, 7]. Thus, better biomarkers for the
early screening of RA-ILD are eagerly expected.
Micro RNAs (miRNAs) are small non-coding RNAs
with approximate 22 nucleotide length and are stably de-
tected in plasma or serum. It is widely known that miR-
NAs modulate the expression of protein-coding genes at
the post-transcription level and play important roles in
cell activation, proliferation, differentiation, or death.
Dysregulation of miRNAs in the circulation was detected
in the patients with cancer or other diseases and circu-
lating miRNAs could be potential biomarkers for various
diseases [8–10]. Some miRNAs in the circulation were
also dysregulated in inflammatory diseases, such as RA
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[11, 12], inflammatory bowel diseases [13], or idiopathic
pulmonary fibrosis (IPF) [14, 15], though the impact of
the circulating miRNA in inflammatory diseases does
not reach to that in cancer. The expression levels of hsa-
miR-132, hsa-miR-24, and hsa-miR-125a-5p were altered
in plasma from RA patients [12, 16]. The expression
levels of hsa-miR-21 were increased in sera from IPF
patients [14, 15, 17]. However, few studies have fo-
cused on circulating miRNA profiles of RA-ILD. The
present study investigated circulating miRNA profiles
of RA-ILD to determine whether they may be useful
for diagnosing RA-ILD.
Methods
Patients
Sixty four Japanese patients with RA were recruited at
Sagamihara Hospital. ILD was diagnosed from computed
tomography (CT) findings by two physicians specializing
in RA-ILD. RA patients were categorized from A to Z,
based on the Sagamihara Criteria [1]. RA cases in cat-
egories A to D were RA with ILD [ILD(+)RA] and those
in G and H were RA without ILD [ILD(−)RA]. This
study included RA cases in categories A [Findings con-
sistent with ILD were observed in high resolution CT
(HRCT) images (length of shorter diameter of the lesion
was ≥2 cm in a transverse section)] or H [HRCT images
were normal] [1]. RA patients with ILD were further di-
agnosed with one of the two patterns of UIP or NSIP,
based on the predominant CT findings: UIP, irregular
linear opacities and honeycombing; NSIP, bilateral
ground-glass attenuation patterns predominantly in sub-
pleural and basal regions [2, 18, 19]. Plasma samples
from the 64 RA patients with or without ILD were col-
lected and these individual plasma samples were ana-
lyzed for miRNA expression profiles. Blood samples
were taken in tubes with ethylenediaminetetraacetic acid
dipotassium salt (Terumo, Tokyo, Japan) and kept in
room temperature before separation. Plasma was sepa-
rated by centrifugation at 1500 × g for 10 min, and then
stored at −80 °C until analysis. All patients fulfilled the
American College of Rheumatology criteria for RA [20].
This study was reviewed and approved by Sagamihara
Hospital Research Ethics Committee and University of
Tsukuba Research Ethics Committee. Written informed
consent was obtained from all study participants. This
study was conducted in accordance with the principles
expressed in the Declaration of Helsinki.
MiRNA analysis
RNA was isolated from 200 μl plasma samples using miR-
CURY RNA Isolation kit Biofluids (Exiqon, Vedbaek,
Denmark) and complementary DNA (cDNA) was synthe-
sized with miRCURY LNA Universal cDNA Synthesis kit II
(Exiqon). Real-time RT-PCR analysis was performed to
evaluate miRNA expression in the plasma pool from 17 RA
patients with RA-ILD or the pool from 17 RA patients
without ILD, using Human miRNome microRNA PCR
Panel I + II (Exiqon), ExiLENT SYBR Green master mix
(Exiqon), and LightCycler 480 System II (Roche, Basel,
Switzerland). Thermal cycling conditions consisted of initial
denaturation at 95 °C for 10 min, followed by 45 cycles of
95 °C for 10 s followed by 60 °C for 1 min. Interplate cali-
bration was conducted by the subtraction of the average Cт
values of UniSP3 probe of the plate. The levels of miRNA
among plasma samples were normalized to the average ex-
pression of five circulating miRNAs; hsa-miR-425-5p, hsa-
miR-423-5p, hsa-miR-103a-3p, hsa-miR-191-5p, hsa-miR-
93-5p. The amount of miRNA was quantified using com-
parative Cт method. The two pooled plasma of ILD(+)RA
or ILD(−)RA were screened for the miRNA profiling. The
data obtained from the microRNA PCR panels were depos-
ited in Gene Expression Omnibus of National Center for
Biotechnology Information and are accessible by accession
number GSE88899. The PCR panel contains 752 probes for
human miRNAs. Potential miRNA markers were selected
for real-time RT-PCR analysis of miRNAs in individual pa-
tient plasma, based on the PCR panel data; eight miRNAs
with higher absolute ⊿⊿Cт values (The ⊿⊿Cт values of
these eight miRNAs were higher than 3.12) were selected
when the samples with undefined Cт values of wells for de-
tection of gene of interest were eliminated for the selection.
Other eight miRNAs with higher absolute⊿⊿Cт values
(The ⊿⊿Cт values of these eight miRNAs were higher than
5.10) were selected when the undefined CT values were
substituted by 40. Thus, sixteen miRNAs were selected for
the individual analysis.
Pick-&-Mix microRNA PCR Panel (Exiqon), ExiLENT
SYBR Green master mix (Exiqon), and Applied Biosys-
tems 7500 Fast Real-Time PCR System (Thermo Fisher
Scientific, Waltham, MA, USA) were employed for the
detection of miRNAs in each individual plasma sample
from 64 RA patients with or without RA-ILD that in-
clude the above-mentioned 34 RA patients in the
screening. The same thermal cycling condition was used.
The expression levels of miRNAs in the samples with
undefined Cт values were define to be 0. The levels of
miRNA among plasma samples were normalized to the
average expression of three circulating miRNAs; hsa-
miR-103a-3p, hsa-miR-191-5p, hsa-miR-93-5p. Relative
expression levels of miRNAs in plasma were calculated
with comparative Cт method.
Statistical analysis
Differences in patient characteristics were analyzed by
Mann-Whitney’s U test or Fisher’s exact test using 2X2
contingency tables. Mann-Whitney’s U test was con-
ducted for the comparison of miRNA expression levels.
Multiple linear regression analysis was performed to
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develop miRNA index for ILD in RA from miRNA
levels. Correction for multiple testing was performed by
calculating false discovery rate Q-value [21]. Target
genes for the miRNAs were predicted using target pre-
diction algorithm at miRDB (http://mirdb.org) [22].
Results
Clinical features of the RA patients
Characteristics of the RA patients are shown in Table 1.
Mean age, percentage of males, KL-6, SP-D, and disease ac-
tivity score 28 (DAS28) in ILD(+)RA were higher than in
ILD(−)RA. The percentage of administration of biological
disease-modifying anti-rheumatic drugs (DMARDs) in
ILD(+)RA were lower than in ILD(−)RA. Mean age, percent-
age of males, KL-6, and SP-D in RA with ILD of UIP pattern
[UIP(+)RA] were higher than in ILD(−)RA. The percentage
of administration of biological DMARDs in UIP(+)RA were
lower than in ILD(−)RA. Mean age, disease duration, KL-6,
SP-D, DAS28, and DAS28CRP in RA with ILD of NSIP pat-
tern [NSIP(+)RA] were higher than in ILD(−)RA.
MiRNA expression profiles of RA patients with or without
ILD
Pooled plasma miRNA profiles were compared between
ILD(+)RA and ILD(−)RA groups (Additional file 1: Table
S1). Of 752 tested miRNA, 530 miRNAs were up-
regulated and 217 miRNAs were down-regulated in
ILD(+)RA. Sixteen miRNAs with higher absolute ⊿⊿Cт
values were selected for further analysis on the individ-
ual plasmas, as described in Materials and methods (in-
dicated in red, Additional file 1: Table S1).
Sixteen miRNAs as potential biomarkers (hsa-miR-
29c-3p, hsa-miR-154-5p, hsa-miR-543, hsa-miR-214-5p,
hsa-miR-382-3p, hsa-let-7g-3p, hsa-miR-9-5p, hsa-miR-
370-3p, hsa-miR-221-5p, hsa-miR-483-5p, hsa-miR-7-5p,
hsa-miR-376b-3p, hsa-miR-487b-3p, hsa-let-7f-1-3p,
hsa-miR-500a-5p, hsa-miR-582-5p) were selected for
further analysis of miRNAs in individual patient plasma.
The 16 miRNAs were also compared between the
ILD(+)RA and ILD(−)RA using the real-time RT-PCR
method (Table 2 and Additional file 2: Figure S1). The
results show a tendency for the expression levels of hsa-
miR-214-5p and hsa-miR-7-5p to be increased in the
ILD(+)RA group (Fig. 1a and b). Although, male per-
centage is higher in the ILD(+)RA group, the expression
levels of 16 selected miRNAs were not different between
male and female in the ILD(+)RA group (Additional file
3: Table S2). The effects of the age on the expression
levels of some miRNAs were detected (Additional file 4:
Table S3). The effects of the DAS28 on the expression
Table 1 Characteristics of the RA patients
ILD(+)RA UIP(+)RA NSIP(+)RA
ILD(+)RA UIP(+)RA NSIP(+)RA ILD(−)RA P P P
Number 32 18 14 32
Age year 70.2 (7.4) 70.6 (8.0) 69.6 (6.8) 57.7 (13.8) 0.0002 0.0013 0.0043
male number n (%) 11 (34.4) 9 (50.0) 2 (14.3) 2 (6.3) *0.0109 *0.0007 *0.5745
Disease duration year 15.5 (12.6) 12.8 (12.2) 18.9 (12.7) 10.6 (7.4) 0.1830 0.8953 0.0116
Steinbrocker stage III and IV n (%) 18 (56.3) 9 (50.0) 9 (64.3) 21 (65.6) *0.6088 *0.3701 *1.0000
Smoker or past smoker n (%) 10 (33.3) 7 (38.9) 3 (25.0) 10 (32.3) *1.0000 *0.7581 *0.7272
Rheumatoid factor positive n (%) 30 (93.8) 17 (94.4) 13 (92.9) 27 (84.4) *0.4258 *0.3991 *0.6506
Anti-citrullinated peptide antibody positive n (%) 31 (96.9) 18 (100.0) 13 (92.9) 31 (96.9) *1.0000 *1.0000 *0.5208
KL-6 U/ml 1096.4 (853.7) 1086.2 (828.4) 1108.8 (914.9) 315.3 (257.9) 2.44 × 10−7 2.97 × 10−6 0.0001
SP-D ng/ml 194.1 (244.7) 177.3 (192.3) 214.5 (303.0) 46.0 (37.5) 2.48 × 10−5 0.0008 0.0001
DAS28 4.0 (1.2) 3.7 (1.3) 4.3 (0.9) 3.1 (1.2) 0.0040 0.0793 0.0021
DAS28-CRP 3.0 (1.3) 2.6 (1.4) 3.4 (1.0) 2.4 (1.0) 0.0500 0.5855 0.0035
NSAIDs administration n (%) 13 (41.9) 7 (38.9) 6 (46.2) 15 (48.4) *0.7989 *0.5647 *1.0000
Corticosteroid administration n (%) 26 (83.9) 14 (77.8) 12 (92.3) 25 (80.6) *1.0000 *1.0000 *0.6542
DMARDs administration n (%) 24 (77.4) 14 (77.8) 10 (76.9) 30 (96.8) *0.0529 *0.0542 *0.0706
sDMARDs administration n (%) 19 (61.3) 11 (61.1) 8 (61.5) 19 (61.3) *1.0000 *1.0000 *1.0000
bDMARDs administration n (%) 10 (32.3) 5 (27.8) 5 (38.5) 22 (71.0) *0.0048 *0.0066 *0.0874
Average values or numbers of each group are shown. Standard deviations or percentages are shown in parenthesis. Differences were tested by Mann-Whitney’s U
test or Fisher’s exact test using 2 × 2 contingency tables
RA rheumatoid arthritis, ILD interstitial lung disease, UIP Usual interstitial pneumonia, NSIP Nonspecific interstitial pneumonia, ILD(+)RA RA with ILD, UIP(+)RA RA
with ILD of UIP pattern, NSIP(+)RA RA with ILD of NSIP pattern, ILD(−)RA RA without ILD, KL-6 krebs von den lungen-6, SP-D Surfactant protein-D, DAS28 disease ac-
tivity score 28, NSAIDs non-steroidal anti- inflammatory drug, DMARD disease-modifying anti-rheumatic drug, sDMARD synthetic DMARD, bDMARD
biological DMARD
*Fisher’s exact test was employed
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levels of miRNAs could not be detected in the present
study (Additional file 5: Table S4). The effects of the bio-
logical DMARDs on the expression levels of miRNA
were not found (Additional file 6: Table S5). For hsa-
miR-214-5p, 135 target genes were predicted and in-
clude SMAD4, coding a protein involved in signal trans-
duction of the transforming growth factor β [23]. For
hsa-miR-7-5p, 434 target genes were predicted and in-
clude BLOC1S4. The mutation of Bloc1s4 causes a
model of Hermansky-Pudlak syndrome [24].
The area under the curve (AUC) value of the receiver
operating characteristic (ROC) curve for hsa-miR-214-
5p was 0.634 and that for hsa-miR-7-5p was 0.652
(Fig. 1c). Specificities and sensitivities of these miRNAs
were estimated from the ROC curve conditional on the
highest Youden’s index. The optimized cut-off level of
hsa-miR-214-5p was 0.429 with the sensitivity (0.375)
and the specificity (0.906). The optimized cut-off level of
hsa-miR-7-5p was 5.686 with the sensitivity (0.469) and
the specificity (0.875).
An miRNA index (214, 7) was generated from the ex-
pression levels of hsa-miR-214-5p and hsa-miR-7-5p and
evaluated as a marker for ILD(+)RA; miRNA index (214,
7) = 0.0095 X hsa-miR-214-5p + 0.0008 X hsa-miR-7-5p.
The miRNA index (214, 7) was higher in the ILD(+)RA
group (Fig. 1d, Table 2, P =0.0010, Q = 0.0162, mean ±
SD = 0.122 ± 0.332 in ILD(+)RA, 0.006 ± 0.013 in
ILD(−)RA). The AUC value of the ROC curve for the
miRNA index (214, 7) was 0.740 (Fig. 1e). Specificities
and sensitivities of miRNA index (214, 7) were estimated
from the ROC curve conditional on the highest Youden’s
index. The optimized cut-off level was 0.004 with the
sensitivity (0.656) and specificity (0.813). Thus, the
plasma miRNA profiles were different between
ILD(+)RA and ILD(−)RA groups.
MiRNA expression profiles of RA patients with UIP or NSIP
patterns
The expression levels of the 16 miRNAs were compared
between the UIP(+)RA and ILD(−)RA. A tendency for
the expression levels of hsa-miR-214-5p and hsa-miR-7-
5p to be increased in the UIP(+)RA group was also ob-
served. The values of miRNA index (214, 7) in the
UIP(+)RA group was higher (P = 0.0005, Q = 0.0093,
mean ± SD = 0.202 ± 0.430 in UIP(+)RA). The expression
pattern of the 16 miRNAs were also compared between
the NSIP(+)RA and ILD(−)RA. No association was ob-
served in the NSIP(+)RA group. Thus, miRNA profiles
were also altered in UIP(+)RA groups.
Discussion
It was reported that plasma miRNA profiles are altered
not only in cancerous patients [8–10], but also in pa-
tients with inflammatory diseases [11–15]. However, few
Table 2 miRNA profiles of the RA patients with or without ILD
ILD(+)RA UIP(+)RA NSIP(+)RA
miRNA ILD(+)RA UIP(+)RA NSIP(+)RA ILD(−)RA P FDR Q P FDR Q P FDR Q
hsa-miR-29c-3p 28.7 (92.4) 45.9 (121.6) 6.7 (10.4) 2.9 (2.5) 0.1772 0.6025 0.0499 0.1698 0.9334 0.9334
hsa-miR-154-5p 17.9 (59.1) 24.6 (76.8) 9.3 (21.3) 2.0 (2.8) 0.9238 0.9815 0.5331 0.7294 0.3604 0.7416
hsa-miR-543 11.0 (35.9) 14.8 (46.6) 6.1 (13.9) 1.4 (1.4) 0.4386 0.6213 0.8633 0.9173 0.1145 0.6099
hsa-miR-214-5p 8.1 (28.2) 13.6 (37.0) 1.0 (3.2) 0.2 (0.9) 0.0156 0.1322 0.0076 0.0643 0.1697 0.6099
hsa-miR-382-3p 10.9 (41.5) 14.8 (52.9) 5.8 (19.9) 0.9 (1.7) 0.4279 0.6213 0.9473 0.9473 0.1794 0.6099
hsa-let-7g-3p 29.1 (107.3) 50.3 (141.1) 1.9 (3.7) 3.3 (5.3) 0.6098 0.7974 0.5578 0.7294 0.1095 0.6099
hsa-miR-9-5p 5.8 (18.5) 9.1 (24.2) 1.5 (4.2) 0.9 (2.6) 0.8510 0.9815 0.7724 0.8753 0.4947 0.7416
hsa-miR-370-3p 12.2 (57.4) 18.2 (76.3) 4.5 (11.1) 0.3 (0.4) 0.8766 0.9815 0.3648 0.6202 0.4734 0.7416
hsa-miR-221-5p 17.1 (53.1) 26.6 (68.7) 5.0 (16.6) 0.7 (1.2) 0.3227 0.6213 0.0461 0.1698 0.5235 0.7416
hsa-miR-483-5p 80.7 (331.8) 130.5 (440.8) 16.6 (24.4) 14.3 (33.9) 0.2827 0.6213 0.2330 0.4951 0.6161 0.7888
hsa-miR-7-5p 56.2 (260.4) 91.1 (347.0) 11.5 (19.9) 4.7 (11.8) 0.0362 0.2049 0.0275 0.1559 0.2616 0.6571
hsa-miR-376b-3p 14.6 (48.8) 19.0 (63.4) 9.0 (19.3) 1.1 (1.4) 0.3718 0.6213 0.2621 0.4951 0.7915 0.8751
hsa-miR-487b-3p 12.7 (56.4) 19.1 (75.0) 4.4 (10.2) 0.5 (0.7) 0.2437 0.6213 0.1181 0.2868 0.8237 0.8751
hsa-let-7f-1-3p 24.9 (114.7) 39.8 (153.0) 5.7 (9.4) 2.6 (2.8) 0.9893 0.9893 0.6856 0.8326 0.6496 0.7888
hsa-miR-500a-5p 55.8 (230.6) 94.7 (305.3) 5.7 (12.3) 1.7 (4.6) 0.3744 0.6213 0.4566 0.7056 0.4823 0.7416
hsa-miR-582-5p 144.8 (288.5) 208.4 (360.8) 63.0 (124.4) 31.5 (60.5) 0.0693 0.2946 0.0705 0.1998 0.2706 0.6571
miRNA Index (214, 7) 0.122 (0.332) 0.202 (0.430) 0.019 (0.034) 0.006 (0.013) 0.0010 0.0162 0.0005 0.0093 0.0732 0.6099
Average values of each group are shown. Standard deviations are shown in parenthesis. Differences were tested by Mann-Whitney’s U test. To correct for multiple
testing, the false discovery rate Q-value was calculated
RA rheumatoid arthritis, ILD interstitial lung disease, UIP Usual interstitial pneumonia, NSIP Nonspecific interstitial pneumonia, ILD(+)RA RA with ILD, UIP(+)RA RA
with ILD of UIP pattern, NSIP(+)RA RA with ILD of NSIP pattern, ILD(−)RA RA without ILD
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studies have focused on miRNA profiling in RA-ILD,
though these could be diagnostic markers overcoming
the existing markers with low sensitivity [6, 7]. We have
tried to discriminate RA-ILD, one of the potentially life-
threatening extra-articular manifestations of RA, using
plasma miRNA profiles. To the best of our knowledge,
this is the first report of plasma miRNA profiles in RA-
ILD. We found that hsa-miR-214-5p and hsa-miR-7-5p
were increased in the ILD(+)RA group (Fig. 1a and b),
though the superiority of these miRNA profiles was not
observed compared with KL-6 (AUC = 0.86, cut-off level
= 331.5, sensitivity =0.769, and specificity =0.842) [7].
It was already well known that cancer cells produce
circulating extracellular miRNAs in plasma samples
from cancerous patients. Inflammatory cells or tissues
may also produce circulating extracellular miRNAs in
plasma samples from patients with inflammatory dis-
eases. Thus, hsa-miR-214-5p and hsa-miR-7-5p might be
preferentially produced by inflammatory cells or tissues.
Though the expression levels of hsa-miR-21 were in-
creased in sera from IPF patients [14, 15, 17], this in-
crease was not observed in the pooled sera from the
ILD(+)RA group (Additional file 1: Table S1). This dis-
crepancy could be explained by the difference between
the pathogenesis of IPF that includes only UIP and that
of RA-ILD that includes both UIP and NSIP.
Since miRNAs modulate the expression of protein-
coding genes at the post-transcription level, many stud-
ies on the expression and the function of miRNAs were
reported. It was reported that the expression levels of
hsa-miR-214-5p were increased in B cell lymphoma with
better prognosis [25] and liver cirrhosis [26], but de-
creased in hepatocellular carcinoma [27]. The expression
of hsa-miR-7-5p inhibits melanoma cell migration [28],
and the decreased expression levels of hsa-miR-7-5p in
follicular thyroid cancer were thought to be a reliable
Fig. 1 Evaluation of the miRNA expression levels, as a marker for interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. a Distribution of the
hsa-miR-214-5p. The filled square, filled circle, and empty circle represent RA without ILD, RA with usual interstitial pneumonia, and RA with nonspecific interstitial
pneumonia, respectively. Horizontal bars denote means. The horizontal dotted line represents an optimized cut-off level (hsa-miR-214-5p= 0.429, with specificity
and sensitivity of 0.906 and 0.375, respectively). ILD(+)RA: RA with ILD, ILD(−)RA: RA without ILD. b Distribution of the hsa-miR-7-5p. The horizontal dotted line
represents an optimized cut-off level (hsa-miR-7-5p = 5.686, with specificity and sensitivity of 0.875 and 0.469, respectively). c The receiver operating
characteristic (ROC) curve using the hsa-miR-214-5p (dotted line) and hsa-miR-7-5p (solid line) as markers for ILD in RA. The area under the curve (AUC)
value of the ROC curve for hsa-miR-214-5p is 0.634 and that for hsa-miR-7-5p is 0.652. d Distribution of miRNA index (214, 7) generated from hsa-miR-
214-5p and hsa-miR-7-5p for ILD (=0.0095 X hsa-miR-214-5p + 0.0008 X hsa-miR-7-5p). The horizontal dotted line represents an optimized cut-off level
(miRNA index (214, 7) = 0.004, with specificity and sensitivity of 0.813 and 0.656, respectively). e The ROC curve using miRNA index (214, 7) as a marker
for ILD in RA. The AUC value of the ROC curve is 0.740
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marker [29]. The expression levels of hsa-miR-7-5p were
increased in dental pulp stem cells [30]. The altered expres-
sion levels of hsa-miR-7-5p were also reported in breast
cancer and glioblastoma [31–33]. Thus, the altered expres-
sion patterns and the function of hsa-miR-214-5p and hsa-
miR-7-5p have been reported. The target genes of the two
miRNAs were predicted. Although many genes were pre-
dicted, some predicted genes, including SMAD4 and
BLOC1S4, are known to be involved in the pathogenesis of
ILD. However, further functional studies on these miRNAs
would be expected to provide better understanding of the
roles of these miRNA for the pathogenesis of RA-ILD.
Because of the limited sample size, the validation of
miRNA profiles should be performed in future inde-
pendent work. For the practical applications of miRNA
biomarkers for RA-ILD, the expression patterns of all
miRNAs should be comprehensively investigated. There-
fore, further large-scale miRNA profiling using next gen-
eration sequencer could be expected.
Conclusions
This is the first report of plasma miRNA profiles of RA-
ILD. The expression levels of hsa-miR-214-5p and hsa-
miR-7-5p were increased in the ILD(+)RA group and
they could be potential biomarkers for ILD in RA.
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